JOHN G MICKELSON
- Type
- Physician · Allopathic & Osteopathic Physicians / Family Medicine
- Where
- FARGO, ND
- NPI
- 1497773097
- Received
- $859,173 in 10 records, 2024 to 2025 ($16 general, $859,156 research)
- As principal investigator
- $2,116,209 of research payments to others in 17 records
- Source
- CMS Open Payments search ↗
By year
| Program year | Kind | Records | Amount |
|---|---|---|---|
| 2024 | General payment | 1 | $16 |
| 2024 | Research payment | 9 | $859,156 |
By company
| Company | Records | Amount | Years |
|---|---|---|---|
| Amneal Pharmaceuticals LLC | 9 | $859,156 | 2024 |
| Medtronic, Inc. | 1 | $16 | 2024 |
By nature of payment
| Nature | Records | Amount |
|---|---|---|
| Research payment | 9 | $859,156 |
| Food and Beverage | 1 | $16 |
Records
| Date | Company | Amount | Nature | Form | Product | Study | Year |
|---|---|---|---|---|---|---|---|
| 2024-10-15 | Amneal Pharmaceuticals LLC | $359,896 | Research payment | Cash or cash equivalent | CREXONT Drug, NEUROLOGY | Supratherapeutic Dose of Carbidopa in Healthy Subjects | 2024 |
| 2024-07-17 | Medtronic, Inc. | $16 | Food and Beverage | In-kind items and services | IN.PACT ADMIRAL Device, Drug-Coated Balloons | 2024 | |
| 2024-06-26 | Amneal Pharmaceuticals LLC | $21,708 | Research payment | Cash or cash equivalent | CREXONT Drug, NEUROLOGY | A Three-Way Crossover Thorough QT/QTc Study to Evaluate the Electrocardiographic Effects of a Supratherapeutic Dose of C | 2024 |
| 2024-02-02 | Amneal Pharmaceuticals LLC | $92,062 | Research payment | Cash or cash equivalent | A THREE-WAY CROSSOVER THOROUGH QT/QTC STUDY TO EVALUATE THE ELECTROCARDIOGRAPHIC EFFECTS OF A SUPRATHERAPEUTIC DOSE OF C | 2024 | |
| 2024-02-02 | Amneal Pharmaceuticals LLC | $92,062 | Research payment | Cash or cash equivalent | CREXONT Drug, NEUROLOGY | A Three-Way Crossover Thorough QT/QTc Study to Evaluate the Electrocardiographic Effects of a Supratherapeutic Dose of C | 2024 |
| 2024-02-02 | Amneal Pharmaceuticals LLC | $67,512 | Research payment | Cash or cash equivalent | A THREE-WAY CROSSOVER THOROUGH QT/QTC STUDY TO EVALUATE THE ELECTROCARDIOGRAPHIC EFFECTS OF A SUPRATHERAPEUTIC DOSE OF C | 2024 | |
| 2024-02-02 | Amneal Pharmaceuticals LLC | $67,512 | Research payment | Cash or cash equivalent | CREXONT Drug, NEUROLOGY | A Three-Way Crossover Thorough QT/QTc Study to Evaluate the Electrocardiographic Effects of a Supratherapeutic Dose of C | 2024 |
| 2024-02-02 | Amneal Pharmaceuticals LLC | $11,690 | Research payment | Cash or cash equivalent | A THREE-WAY CROSSOVER THOROUGH QT/QTC STUDY TO EVALUATE THE ELECTROCARDIOGRAPHIC EFFECTS OF A SUPRATHERAPEUTIC DOSE OF C | 2024 | |
| 2024-02-02 | Amneal Pharmaceuticals LLC | $11,690 | Research payment | Cash or cash equivalent | CREXONT Drug, NEUROLOGY | A Three-Way Crossover Thorough QT/QTc Study to Evaluate the Electrocardiographic Effects of a Supratherapeutic Dose of C | 2024 |
| 2024-01-12 | Amneal Pharmaceuticals LLC | $135,024 | Research payment | Cash or cash equivalent | CREXONT Drug, NEUROLOGY | A Three-Way Crossover Thorough QT/QTc Study to Evaluate the Electrocardiographic Effects of a Supratherapeutic Dose of C | 2024 |
Research payments naming this person as principal investigator
| Date | Company | Paid to | Amount | Study | Year |
|---|---|---|---|---|---|
| 2025-07-09 | Eli Lilly and Company | AXIS CLINICALS LLC | $7,590 | A PHASE 1, DOUBLE-BLIND, TWO-ARM, MECHANISM OF ACTION STUDY TO INVESTIGATE THE EFFECT OF ORFORGLIPRON ON BODY COMPOSITIO | 2025 |
| 2025-05-19 | Eli Lilly and Company | AXIS CLINICAL TRIALS | $28,576 | A PHASE 1, DOUBLE-BLIND, TWO-ARM, MECHANISM OF ACTION STUDY TO INVESTIGATE THE EFFECT OF ORFORGLIPRON ON BODY COMPOSITIO | 2025 |
| 2025-04-30 | Eli Lilly and Company | AXIS CLINICALS LLC | $936,718 | A PHASE 1, DOUBLE-BLIND, TWO-ARM, MECHANISM OF ACTION STUDY TO INVESTIGATE THE EFFECT OF ORFORGLIPRON ON BODY COMPOSITIO | 2025 |
| 2024-09-26 | ABBVIE INC. | AXIS CLINICALS LLC | $19,933 | A Trial to Evaluate the Effect of Esomeprazole on the Pharmacokinetics of Emraclidine in Healthy Adult Participants | 2024 |
| 2023-12-28 | Amneal Pharmaceuticals LLC | AXIS RESEARCH INC | $105,012 | A THREE-WAY CROSSOVER THOROUGH QT/QTC STUDY TO EVALUATE THE ELECTROCARDIOGRAPHIC EFFECTS OF A SUPRATHERAPEUTIC DOSE OF C | 2023 |
| 2023-12-17 | Amneal Pharmaceuticals LLC | AXIS RESEARCH INC | $27,000 | A THREE-WAY CROSSOVER THOROUGH QT/QTC STUDY TO EVALUATE THE ELECTROCARDIOGRAPHIC EFFECTS OF A SUPRATHERAPEUTIC DOSE OF C | 2023 |
| 2023-12-14 | Amneal Pharmaceuticals LLC | AXIS RESEARCH INC | $164,114 | A THREE-WAY CROSSOVER THOROUGH QT/QTC STUDY TO EVALUATE THE ELECTROCARDIOGRAPHIC EFFECTS OF A SUPRATHERAPEUTIC DOSE OF C | 2023 |
| 2023-12-10 | Amneal Pharmaceuticals LLC | AXIS RESEARCH INC | $23,524 | A THREE-WAY CROSSOVER THOROUGH QT/QTC STUDY TO EVALUATE THE ELECTROCARDIOGRAPHIC EFFECTS OF A SUPRATHERAPEUTIC DOSE OF C | 2023 |
| 2023-11-30 | Amneal Pharmaceuticals LLC | AXIS RESEARCH INC | $135,024 | A THREE-WAY CROSSOVER THOROUGH QT/QTC STUDY TO EVALUATE THE ELECTROCARDIOGRAPHIC EFFECTS OF A SUPRATHERAPEUTIC DOSE OF C | 2023 |
| 2023-11-03 | Amneal Pharmaceuticals LLC | AXIS RESEARCH INC | $337,559 | A THREE-WAY CROSSOVER THOROUGH QT/QTC STUDY TO EVALUATE THE ELECTROCARDIOGRAPHIC EFFECTS OF A SUPRATHERAPEUTIC DOSE OF C | 2023 |
| 2023-07-16 | Amneal Pharmaceuticals LLC | AXIS RESEARCH INC | $81,817 | A THREE-WAY CROSSOVER THOROUGH QT/QTC STUDY TO EVALUATE THE ELECTROCARDIOGRAPHIC EFFECTS OF A SUPRATHERAPEUTIC DOSE OF C | 2023 |
| 2023-07-14 | Amneal Pharmaceuticals LLC | AXIS RESEARCH INC | $3,709 | A THREE-WAY CROSSOVER THOROUGH QT/QTC STUDY TO EVALUATE THE ELECTROCARDIOGRAPHIC EFFECTS OF A SUPRATHERAPEUTIC DOSE OF C | 2023 |
| 2023-06-30 | Amneal Pharmaceuticals LLC | AXIS RESEARCH INC | $11,785 | A THREE-WAY CROSSOVER THOROUGH QT/QTC STUDY TO EVALUATE THE ELECTROCARDIOGRAPHIC EFFECTS OF A SUPRATHERAPEUTIC DOSE OF C | 2023 |
| 2023-06-11 | Amneal Pharmaceuticals LLC | AXIS RESEARCH INC | $12,960 | A THREE-WAY CROSSOVER THOROUGH QT/QTC STUDY TO EVALUATE THE ELECTROCARDIOGRAPHIC EFFECTS OF A SUPRATHERAPEUTIC DOSE OF C | 2023 |
| 2023-02-04 | Amneal Pharmaceuticals LLC | AXIS RESEARCH INC | $106,761 | A THREE-WAY CROSSOVER THOROUGH QT/QTC STUDY TO EVALUATE THE ELECTROCARDIOGRAPHIC EFFECTS OF A SUPRATHERAPEUTIC DOSE OF C | 2023 |
| 2023-01-15 | Amneal Pharmaceuticals LLC | AXIS RESEARCH INC | $7,190 | A THREE-WAY CROSSOVER THOROUGH QT/QTC STUDY TO EVALUATE THE ELECTROCARDIOGRAPHIC EFFECTS OF A SUPRATHERAPEUTIC DOSE OF C | 2023 |
| 2023-01-15 | Amneal Pharmaceuticals LLC | AXIS RESEARCH INC | $106,932 | A THREE-WAY CROSSOVER THOROUGH QT/QTC STUDY TO EVALUATE THE ELECTROCARDIOGRAPHIC EFFECTS OF A SUPRATHERAPEUTIC DOSE OF C | 2023 |
CMS Open Payments: payments and transfers of value that drug and medical device makers and group purchasing organizations report to Medicare, program years 2019 on, as published by CMS (general, research and ownership records; refreshed by CMS each June and January). Links to other records on this site are by name (and state) only.
The area Census
County outline, the place (blue), the tract (orange) and the ZIP center (dot).
In Fargo, ND, county Cass County, ND, state North Dakota; placed by its city name.
| Measure | Place (city or town) Fargo, ND | County Cass County, ND | State North Dakota |
|---|---|---|---|
| Population B01003 | 131,627 | 193,400 | 784,841 |
| Population, 2020 census P1 | 125,990 | 184,525 | 779,094 |
| Median age B01002 | 31.8 | 32.8 | 35.9 |
| Under 18 B01001 | 20.0% | 22.2% | 23.5% |
| 65 and over B01001 | 13.3% | 13.0% | 16.5% |
| Households B11001 | 59,970 | 83,945 | 331,063 |
| Foreign born B05002 | 9.5% | 7.7% | 4.7% |
| Median household income B19013 | $66,998 | $75,555 | $76,657 |
| Median family income B19113 | $102,528 | $109,848 | $104,993 |
| Per capita income B19301 | $42,734 | $45,643 | $43,389 |
| Poverty rate B17001 | 12.9% | 11.0% | 10.8% |
| Unemployment rate B23025 | 3.8% | 3.0% | 2.8% |
| Civilian labor force B23025 | 79,804 | 115,503 | 417,808 |
| Mean commute (minutes) B08013 | 15.5 | 17.1 | 17.9 |
| Bachelor's degree or higher B15003 | 42.9% | 42.6% | 32.7% |
| Housing units B25001 | 63,807 | 89,038 | 377,281 |
| Owner-occupied B25003 | 43.7% | 52.0% | 62.9% |
| Renters B25003 | 56.3% | 48.0% | 37.1% |
| Median home value B25077 | $281,900 | $298,000 | $249,900 |
| Median gross rent B25064 | $946 | $958 | $954 |
| White, not Hispanic B03002 | 78.6% | 81.2% | 81.7% |
| Black B03002 | 8.6% | 7.0% | 3.3% |
| Hispanic or Latino B03002 | 3.6% | 3.6% | 4.7% |
| Asian B03002 | 4.0% | 3.2% | 1.6% |
| American Indian and Alaska Native B03002 | 0.9% | 0.9% | 4.2% |
Data: IPUMS NHGIS (ACS 2020-2024 and the 2020 census); each figure links to its table for that area at data.census.gov. Records are placed by ZIP code and city name, not street address. More: everything FURP has in Fargo, ND.
Comments